Climb Bio (CLYM) Assets Average (2021 - 2026)

Climb Bio filings provide 6 years of Assets Average readings, the most recent being $160.1 million for Q1 2026.

  • Quarterly Assets Average fell 23.4% to $160.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $160.1 million through Mar 2026, down 23.4% year-over-year, with the annual reading at $192.5 million for FY2025, 17.48% up from the prior year.
  • Assets Average hit $160.1 million in Q1 2026 for Climb Bio, down from $175.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $224.1 million in Q3 2024 and bottomed at $109.9 million in Q1 2024.
  • Average Assets Average over 5 years is $160.6 million, with a median of $160.1 million recorded in 2026.
  • The largest annual shift saw Assets Average decreased 23.73% in 2023 before it surged 96.85% in 2024.
  • Climb Bio's Assets Average stood at $137.9 million in 2022, then dropped by 19.09% to $111.6 million in 2023, then surged by 96.85% to $219.7 million in 2024, then dropped by 20.33% to $175.0 million in 2025, then fell by 8.55% to $160.1 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Assets Average are $160.1 million (Q1 2026), $175.0 million (Q4 2025), and $187.3 million (Q3 2025).